This is the authors' abstract. We don't add key points for this paper.
Simple Summary Multiple myeloma (MM) is characterized by monoclonal plasma cell proliferation in the bone marrow. p53 plays a critical role in MM and the 17p deletion is associated with poor clinical outcomes. Rho-GTPase signaling, which includes Ras-related C3 botulinum toxin substrate 1 (Rac1) as a major regulator, is involved in cancer progression and chemoresistance; however, the role of Rac1 in MM remains elusive. This study was conducted to evaluate the role of Rac1 in MM. The results revealed that Rac1 affected the survival of human MM cell lines (HMCLs) independent of p53 status. High RAC1 mRNA expression in the intramedullary plasma cells of patients with NDMM was associated with poor overall survival. The Rac1 inhibitor intensified the effect of cereblon modulators on HMCLs. This study presents new insights into developing novel therapies targeting the Rac1 pathway, potentially improving the prognosis of patients with MM, including those with Wild Type p53 deficiency.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Matsumura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: